If this finding could be broadly translated into clinical efficacy in heterogeneous HNSCC tumors (50–80% mutant p53, 60–80% of oropharynx tumors are HPV positive), H-4073 could represent a promising new agent for targeted therapy in HNSCC. The gene discussed is TP53; the disease is neoplasm of oropharynx.